Vicor Technologies, Inc. (VCRT) Responds to FDA for Marketing Claim on PD2i® Technology
Vicor Technologies, Inc. filed its premarket notification paperwork with the U.S. Food and Drug Administration in 2010 required to receive 510(k) clearance for a Cardiac Marketing Claim on its proprietary PD2i® nonlinear algorithm. The Company’s algorithm and software are to be used in cardiovascular testing and have shown stunning accuracy in testing done to date. Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer™, a non-invasive diagnostic employing its patented PD2i® nonlinear algorithm. The PD2i Analyzer™ enables physicians to accurately risk stratify specific target populations for future pathological events, including diabetics for the presence of…